Joanne Langley, MD

Affiliations

• Professor, Departments of Pediatrics and Community Health & Epidemiology, Faculty of Medicine; Member, Faculty of Graduate Studies, Dalhousie University
• Canadian Institutes of Health Research – GlaxoSmithKline Chair in Pediatric Vaccinology, Dalhousie University
• Active Staff, Pediatric Infectious Diseases, IWK Health Centre

Education

BA, Queen’s University at Kingston
MD, Dalhousie University
MSc (Clinical Epidemiology), McMaster University
Fellow, Royal College of Physicians and Surgeons of Canada (Pediatrics, Infectious Diseases), University of Toronto

Research interests

Dr. Langley is a pediatric infectious disease physician in the Department of Pediatrics and is cross-appointed in the Department of Community Health and Epidemiology in the Faculty of Medicine. She is based at the IWK Health Centre and the Canadian Center for Vaccinology. She conducts studies on the prevention of infectious diseases using vaccines, from phase 1 (first in humans) through to efficacy trials (phase 3) and post-marketing studies of how well vaccines work when they are used in immunization programs (phase 4). These studies are done with collaborators in public health, industry, universities, and non-governmental organizations. Dr. Langley has a particular interest in prevention of respiratory infections such as Respiratory Syncytial Virus and influenza. Her work also focuses on vaccine policy and evidence-based decision making in immunization programs. Dr. Langley is an active investigator in the Canadian Immunization Research Network (CIRN) and co-leads its Clinical Trials Network (CTN). She is co-Chair of the Government of Canada Health Emergency Readiness Agency Council of Expert Advisors, and served on the COVID-19 Science Expert Panel of the Chief Science Advisor of Canada, the COVID-19 Vaccine Task Force, the Canadian Task Force on Preventive Health Care, and Canada’s National Advisory Committee on Immunization (Chair, 2007-2011). Dr. Langley is a Fellow of the Canadian Academy of Health Sciences, the Society for Pediatric Research, the Infectious Disease Society of America, the Pediatric Infectious Disease Society of America and The Society of Healthcare Epidemiology and Infection Control.

Selected publications

• Langley JM, Sadarangani M, Ockenhouse C, Barreto L, Ye L, Tang Y, Breeze JL, Feser J, Hosken NA, Andi-Lolo I, Tasker SA, Halperin SA, the Canadian Immunization Research Network. Safety and immunogenicity of a 25-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve healthy adults: Results from 2 randomised, controlled clinical trials. Vaccine. 2026 Jan;75:128236. Doi.org/10.1016/j.vaccine.2026.128236.
• Sumsuzzman DM, Shi C, Langley JM, Moghadas SM. Nirsevimab Against Hospitalizations and Emergency Department Visits for Lower Respiratory Tract Infection in Infants: A Meta-Analysis. JAMA Pediatr. 2025 Dec 22:e255280. doi: 10.1001/jamapediatrics.2025.5280. Epub ahead of print. PMID: 41428293; PMCID: PMC12723597.
• Sumsuzzman DM, Wang Z, Langley JM, Moghadas SM. Real-world effectiveness of nirsevimab against respiratory syncytial virus disease in infants: a systematic review and meta-analysis. Lancet Child Adolesc Health. 2025 Jun;9(6):393-403. doi: 10.1016/S2352-4642(25)00093-8. Epub 2025 May 1. PMID: 40319903.
• Langley JM, Nolan TM, Rämet M, Richmond PC, Rosário Filho N, Haazen W, van der Berg SPH, Williams K, Bastian AR, Omoruyi E, Williams Durkin J, Salisch N, Van Geet G, van Duijnhoven W, Heijnen E, Callendret B. A Phase 1/2a study evaluating safety and Immunogenicity of Ad26.RSV.preF in RSV-seronegative toddlers aged 12-24 months. Open Forum Infect Dis. 2024;11(9):ofae453. doi: 10.1093/ofid/ofae453. PubMed PMID: 39220658. 
• Langley JM, Gantt S, Halperin SA, Ward B, McNeil S, Ye L, Cai Y, Smith B, Anderson DE, Mitoma FD. An enveloped virus-like particle alum-adjuvanted cytomegalovirus vaccine is safe and immunogenic: a first-in-humans Canadian Immunization Research Network study. Vaccine. 2024;42(3):713-722. doi: 10.1016/j.vaccine.2023.12.019. PubMed PMID: 38142214. 
• Hopman HA, Crowcroft NS, Cesuroglu T, Langley JM. Incorporation of health economic evaluation into immunization policy-making in Canada: Barriers and facilitators. Vaccine. 2020;38(11):2512–2518. PubMed PMID: 32057578..
• View additional publications on PubMed